Human papillomavirus (HPV) is the main cause of cervical cancer, which is one of the most common cancers in women worldwide. TaME-seq (tagmentation-assisted multiplex PCR enrichment sequencing) is a tool for cervical cancer diagnostics and studying of HPV evolution and adaptability. The tool can be used to determine if the patient has a transient or persistent HPV infection where the latter is associated with a higher cancer risk. It is applicable to large sample cohorts leading to reduced sequencing costs.
TaME-seq provides higher clinical specificity than any other HPV test on the market. Current HPV analysis methods are limited to either analysis of HPV variation or chromosomal integration. TaME-seq combines tagmentation and multiplex PCR enrichment for simultaneous analysis of HPV variation and chromosomal integration, and can also be adapted to other viruses.
TaME-seq currently covers HPV16, 18, 31, 33 and 45, being the most common HPV genotypes causing cervical cancer. HPV genomic variability and chromosomal integration are important events in the HPV-induced carcinogenic process. Differences in mutation and integration profiles are characterised in HPV genomes and are linked to persistent infections and cervical carcinogenesis.
Lagström et al, 2019 Sci Rep and J Clin Virol
The provisional patent application entered PCT in November 2019 covers the primer sites and the specialized bioinformatic pipeline and claim diagnostic, prognostic and predictive use of the technology.
Leading HPV scientists at the Cancer Registry of Norway (OUS), Akershus University Hospital, Oslo Metropolitan University and Institute for Molecular Medicine Finland (FIMM) have devleoped TaME-seq and the aim is to establish a diagnostic HPV test to improve the current routines of cervical cancer management.
Inven2 AS seeks partners for co-development and/or licensing of the technology.